COMPANY
Pelagos Pharmaceuticals, Inc.
NIH awards 2
- NIH award 3R41AG079778-01A1S1 FY2023: $90,950 awarded for that fiscal year; activity R41 (STTR); PI CRESAP, MICHELE; recipient as written: PELAGOS PHARMACEUTICALS, INC., HOUSTON, TX. Developing Novel REV-ERB Agonists source ↗
- NIH award 1R41AG079778-01A1 FY2022: $449,482 awarded for that fiscal year; activity R41 (STTR); PI CRESAP, MICHELE; recipient as written: PELAGOS PHARMACEUTICALS, INC., HOUSTON, TX. Developing Novel REV-ERB Agonists source ↗